ElizabethIBuchbinderMD

Oncology • Boston, MA

Hematologic Oncology, Melanoma

Instructor in Medicine, Dana Farber Cancer Institute

Join to view full profile

Dr. Buchbinder is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Buchbinder's full profile

Already have an account?

Office
Dana Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02115
Phone+1 617-632-5055
Is this information wrong?

Summary

Dr. Elizabeth Buchbinder is an oncologist in Boston, MA and is affiliated with multiple hospitals in the area, including Dana-Farber Cancer Institute and Brigham and Women's Hospital. She received her medical degree from Tufts University School of Medicine and has been in practice 13 years. She specializes in hematologic oncology and melanoma and is experienced in melanoma and cutaneous malignancies.

Education & Training

Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2004 - 2007
Tufts University School of MedicineClass of 2004

Certifications & Licensure

NH State Medical License 2023 - 2025
MA State Medical License 2006 - 2025
CT State Medical License 2022 - 2024
ME State Medical License 2022 - 2024
VT State Medical License 2022 - 2024
RI State Medical License 2022 - 2024
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Utility of Novel BRAF Test for Melanoma Start of enrollment: 2013 May 01
Active, not recruiting
LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma Start of enrollment: 2017 Jun 06
Active, not recruiting
Phase 1, Phase 2
A Phase II Study of BVD-523 in Metastatic Uveal Melanoma Start of enrollment: 2018 Mar 26
Active, not recruiting
Phase 2
MCS110 With BRAF/MEK Inhibition in Patients With Melanoma Start of enrollment: 2018 Jun 22
Active, not recruiting
Phase 1, Phase 2
A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma Start of enrollment: 2018 Sep 21
Completed
Phase 3
A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma Start of enrollment: 2019 Sep 06
Withdrawn
Phase 2
Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis Start of enrollment: 2020 Aug 31
Recruiting
Phase 2
A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma Start of enrollment: 2020 Aug 06
Recruiting
Phase 2
Sargramostim (GM-CSF) + PD-1 Start of enrollment: 2021 Apr 16
Withdrawn
Phase 2
Roles: Contact, Principal Investigator
Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma Start of enrollment: 2020 Jun 12
Recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Is There a Current Role for Combination Chemotherapy or High-Dose Interleukin 2 in Melanoma?
Julie Fishman, Elizabeth I Buchbinder> ;Cancer Journal. 2024 Mar 25
Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment.
Baginska, J., Nau, A., Gomez Diaz, I., Giobbie-Hurder, A., Weirather, J., Vergara, J., Abrecht, C., Hallisey, M., Dennis, J., Severgnini, M., Huezo, J., Marciello, I.,...> ;Cancer Immunology, Immunotherapy. 2024 Jan 18
7 citations
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.
Weber, J., Carlino, M., Khattak, A., Meniawy, T., Ansstas, G., Taylor, M., Kim, K., McKean, M., Long, G., Sullivan, R., Faries, M., Tran, T., Cowey, C., Pecora, A., Sh...> ;Lancet. 2024 Feb 17
3 citations
Multicenter Evaluation of Radiation and Immune Checkpoint Inhibitor Therapy in Mucosal Melanoma and Review of Recent Literature.
Smart, A., Giobbie-Hurder, A., Desai, V., Lukens, J., Taunk, N., Sullivan, R., Mooradian, M., Hsu, C., Buchbinder, E., Schoenfeld, J., Xing, J.> ;Advances in Radiation Oncology. 2024 Jan 1
Immunomodulator use, risk factors and management of flares, and mortality for patients with pre-existing rheumatoid arthritis after immune checkpoint inhibitors for ca...
Wang, X., Yoshida, K., Qian, G., Kowalski, E., Vanni, K., McCarter, K., Arabelovic, S., Wolfgang, T., LeBoeuf, N., Buchbinder, E., Gedmintas, L., MacFarlane, L., Rao, ...> ;Seminars in Arthritis and Rheumatism. 2024 Feb 1
2 citations
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0.
Anna C Pavlick, Charlotte E Ariyan, Elizabeth I Buchbinder, Diwakar Davar, Geoffrey T Gibney, Omid Hamid, Tina J Hieken, Benjamin Izar, Douglas B Johnson, Rajan P Kulk...> ;Journal for Immunotherapy of Cancer. 2023 Oct 1
A phase I/II study of LY3022855 with BRAF/MEK inhibition in patients with Melanoma.
Elizabeth I Buchbinder, Anita Giobbie-Hurder, Rizwan Haq, Patrick A Ott> ;Investigational New Drugs. 2023 Aug 1
Brief Communication on Pathologic Assessment of Persistent Stable Metastatic Lesions in Patients Treated With Anti-CTLA-4 or Anti-CTLA-4 + Anti-PD-1 Therapy.
Elizabeth I Buchbinder, Kathleen L Pfaff, Madison M Turner, Michael Manos, Olivia Ouyang, Patrick A Ott, Anita Giobbie-Hurder, Scott J Rodig, F Stephen Hodi> ;Journal of Immunotherapy. 2023 Jun 1
1 citations
A phase I/II study of MCS110 with BRAF/MEK inhibition in patients with melanoma after progression on BRAF/MEK inhibition.
Elizabeth I Buchbinder, Anita Giobbie-Hurder, Patrick A Ott> ;Investigational New Drugs. 2023 Jun 1
Exploring Influencing Factors of Anxiety Improvement Following Mindfulness-Based Music Therapy in Young Adults with Cancer.
Robert Knoerl, Emanuele Mazzola, Heather Woods, Elizabeth Buchbinder, Lindsay Frazier, Ann LaCasce, Marlise R Luskin, Carolyn S Phillips, Katherine Thornton, Donna L B...> ;Journal of Music Therapy. 2023 Jun 3
1 citations
Exploring Young Adults' Perspectives of Participation in a Mindfulness-Based Music Therapy Intervention Before and During the COVID-19 Pandemic.
Carolyn S Phillips, Julianna Bockhoff, Donna L Berry, Elizabeth Buchbinder, A Lindsay Frazier, Ann LaCasce, Jennifer Ligibel, Marlise R Luskin, Heather Woods, Robert K...> ;Journal of Adolescent and Young Adult Oncology. 2023 Aug 1
1 citations
Evolving Management of Stage IV Melanoma.
Benjamin Switzer, Sophie Piperno-Neumann, James Lyon, Elizabeth Buchbinder, Igor Puzanov> ;American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2023 Jan 1
2 citations
Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma.
Selina K Wong, Steven M Blum, Xiaopeng Sun, Inês P Da Silva, Leyre Zubiri, Fei Ye, Kun Bai, Kevin Zhang, Selma Ugurel, Lisa Zimmer, Elisabeth Livingstone, Dirk Schaden...> ;European Journal of Cancer. 2023 Mar 1
1 citations
Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of ...
Joseph M Unger, Amy Darke, Megan Othus, Thach-Giao Truong, Nikhil Khushalani, Kari Kendra, Karl D Lewis, Bryan Faller, Pauline Funchain, Elizabeth I Buchbinder, Ahmad ...> ;JAMA Oncology. 2023 Feb 1
4 citations
Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course.
Aneesha Haryal, Matthew J Townsend, Vinitha Baskaran, Padmavathi Srivoleti, Anita Giobbie-Hurder, Jordan S Sack, Raymond A Isidro, Nicole R LeBoeuf, Elizabeth I Buchbi...> ;Cancer. 2023 Feb 1
1 citations
Topical imiquimod and cryotherapy in combination with systemic immunotherapy in unresectable stage IIIC melanoma.
Jennifer E Yeh, Marilyn T Wan, Allireza Alloo, Nageatte Ibrahim, Patrick A Ott, Elizabeth I Buchbinder, Jennifer Y Lin> ;JAAD Case Reports. 2022 Sep 1
17 citations
Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study.
F Dimitriou, K Namikawa, I L M Reijers, E I Buchbinder, J A Soon, A Zaremba, P Teterycz, M J Mooradian, E Armstrong, Y Nakamura, M G Vitale, L E Tran, X Bai, C Allayou...> ;Annals of Oncology. 2022 Sep 1
4 citations
Overcoming differential tumor penetration of BRAF inhibitors using computationally guided combination therapy.
Thomas S C Ng, Huiyu Hu, Stefan Kronister, Chanseo Lee, Ran Li, Luca Gerosa, Sylwia A Stopka, Danielle M Burgenske, Ishaan Khurana, Michael S Regan, Sreeram Vallabhane...> ;Science Advances. 2022 Apr 29
3 citations
Exploring the Feasibility of a Mindfulness-Music Therapy Intervention to Improve Anxiety and Stress in Adolescents and Young Adults with Cancer.
Robert Knoerl, Emanuele Mazzola, Heather Woods, Elizabeth Buchbinder, Lindsay Frazier, Ann LaCasce, Belinda T Li, Marlise R Luskin, Carolyn S Phillips, Katherine Thorn...> ;Journal of Pain and Symptom Management. 2022 Apr 1
24 citations
Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.
Simone M Goldinger, Kristina Buder-Bakhaya, Serigne N Lo, Andrea Forschner, Meredith McKean, Lisa Zimmer, Chloe Khoo, Reinhard Dummer, Zeynep Eroglu, Elizabeth I Buchb...> ;European Journal of Cancer. 2022 Feb 1
18 citations
Cancer Therapy Targeting CD47/SIRPα.
Elizabeth I Buchbinder, Nazli Dizman> ;Cancers. 2021 Dec 11
17 citations
Adjuvant pembrolizumab versus interferon alfa-2b or ipilimumab in resected high-risk melanoma.
Kenneth F. Grossmann, Megan Othus, Sapna Pradyuman Patel, Ahmad A. Tarhini, Vernon K. Sondak, Michael V. Knopp, Teresa M. Petrella, Thach-Giao Truong, Nikhil I. Khusha...> ;Cancer Discovery. 2021 Nov 11
8 citations
Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial.
Patrick A. Ott, Matthew Nazzaro, Kathleen L. Pfaff, Evisa Gjini, Kristen Felt, Jacquelyn O. Wolff, Elizabeth I. Buchbinder, Rizwan Haq, Ryan J. Sullivan, Donald P. Law...> ;Journal for Immunotherapy of Cancer. 2021 Nov 1
4 citations
Long-term Overall Survival and Predictors in Anti-PD-1-naive Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Settin...
Girish S. Naik, Elizabeth I. Buchbinder, Justine V. Cohen, Michael Manos, Alistair E. W. Johnson, Peter Bowling, Ayal A. Aizer, Jonathan D. Schoenfeld, Donald P. Lawre...> ;Journal of Immunotherapy. 2021 Aug 18
4 citations
Female sex is associated with higher rates of dermatologic adverse events among patients with melanoma receiving immune checkpoint inhibitor therapy: a retrospective c...
Ai-Tram N. Bui, Amina Bougrine, Elizabeth I. Buchbinder, Anita Giobbie-Hurder, Nicole R. LeBoeuf> ;Journal of the American Academy of Dermatology. 2021 Jul 9
Join now to see all

Journal Articles

Prognostic Gene Expression Profiling in Cutaneous Melanoma
Douglas Grossman, Sancy A Leachman, Larissa Korde, Elizabeth I Buchbinder, Emily Y Chu, Julia A Curtis, Laura K Ferris, Kenneth F Grossmann, Siwen Hu-Lieskovan, Joanne..., JAMA Dermatology

Lectures

Characterization of the genetics of mucosal melanoma in patients treated with immunotherapy.
ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019

Authored Content

Prognostic Gene Expression Profiling in Cutaneous MelanomaJuly 2020
Prognostic Gene Expression Profiling in Cutaneous MelanomaJuly 2020
Prognostic Gene Expression Profiling in Cutaneous MelanomaJuly 2020

Press Mentions

Neoadjuvant Immunotherapy Improves Outlook in High-Risk MelanomaFebruary 24th, 2023
Asher Bio Announces Dosing of First Patient in Phase 1a/1b Clinical Trial of AB248, a Cis-Targeted IL-2 Immunotherapy Product Candidate, for the Treatment of Locally Advanced or Metastatic Solid TumorsJanuary 17th, 2023
Neoadjuvant Immunotherapy Improves Outlook in High-Risk MelanomaSeptember 11th, 2022
Join now to see all